Format

Send to

Choose Destination
Nat Rev Drug Discov. 2015 Jul;14(7):475-86. doi: 10.1038/nrd4609. Epub 2015 Jun 19.

An analysis of the attrition of drug candidates from four major pharmaceutical companies.

Author information

1
AstraZeneca, Alderley Park, Cheshire SK10 4TG, UK.
2
Thomson Reuters, 77 Hatton Garden, London EC1N 8JS, UK.
3
GlaxoSmithKline, Stevenage, Hertfordshire SG1 2NY, UK.
4
1] GlaxoSmithKline, Stevenage, Hertfordshire SG1 2NY, UK. [2] Paul Leeson Consulting, The Malt House, Main Street, Congerstone, Nuneaton, Warwickshire CV13 6LZ, UK.
5
Pfizer, Cambridge, Cambridgeshire CB21 6GS, UK.
6
1] Pfizer, Groton, Connecticut 06340, USA. [2] Takeda Pharmaceuticals, Cambridge, Massachusetts 02139, USA.
7
Eli Lilly, Indianapolis, Indiana 46285, USA.
8
1] Eli Lilly, Indianapolis, Indiana 46285, USA. [2] Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, USA.

Abstract

The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development. Attempts to reduce the number of efficacy- and safety-related failures by analysing possible links to the physicochemical properties of small-molecule drug candidates have been inconclusive because of the limited size of data sets from individual companies. Here, we describe the compilation and analysis of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer. The analysis reaffirms that control of physicochemical properties during compound optimization is beneficial in identifying compounds of candidate drug quality and indicates for the first time a link between the physicochemical properties of compounds and clinical failure due to safety issues. The results also suggest that further control of physicochemical properties is unlikely to have a significant effect on attrition rates and that additional work is required to address safety-related failures. Further cross-company collaborations will be crucial to future progress in this area.

PMID:
26091267
DOI:
10.1038/nrd4609
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center